RAPP

Rating neutralAI Memo

Rapport Therapeutics

As of 2026-04-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

RAP-219 Phase 3 program initiation in focal onset seizures • 2026-06-30

Base target: $38 / p=45% prob

Biggest risk

This remains a single-asset-heavy, pre-commercial biotech story with limited near-term external news flow; the stock still depends on Phase 3 start and execution, and any delay, safety surprise, or faster-than-expected burn could compress valuation despite the current cash position [#10-K-2026-03-10].

Invalidation

Break below $24 or thesis failure.

What would change my mind?

RAP-219 has already produced statistically significant Phase 2a proof-of-concept efficacy and tolerability data, management says FDA feedback supported advancement into two parallel Phase 3 trials, and the balance sheet plus Tenacia partnership provide time and some non-dilutive validation to pursue the program [#10-K-2026-03-10].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-17

Base target

$38

p=45%

Bull target

$52

p=25%

Bear target

$24

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 filing to confirm burn and runway after Phase 3 prep
Sustained Phase 3 enrollment and external validation of RAP-219 platform value
RAP-219 has already produced statistically significant Phase 2a proof-of-concept efficacy and tolerability data, management says FDA feedback supported advancement into two parallel Phase 3 trials, and the balance sheet plus Tenacia partnership provide time and some non-dilutive validation to pursue the program [#10-K-2026-03-10].

BearKey bullets

Cash burn accelerates as late-stage studies ramp, reviving dilution risk despite stated runway into 2H29.
Phase 2a tolerability and efficacy do not translate cleanly into larger registrational trials.
Phase 3 initiation slips beyond Q2 2026 or design/execution changes reduce confidence.

WatchKey bullets

RAP-219 Phase 3 program initiation in focal onset seizures

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $38 (p=45%)

Target spread vs base: +37% / -37%

Scenario probabilities

Bull Target: $52 (p=25%)Base Target: $38 (p=45%)Bear Target: $24 (p=30%)

Commentary

Sentiment is cautious rather than outright bullish: Rapport has credible primary-source support for RAP-219's Phase 3 path and a stronger cash position than many micro/mid-cap biotech peers, but the current setup is still mainly a filing-backed monitoring story with limited fresh external confirmation since the March 10, 2026 filings and a negative deterministic directional prior [#10-K-2026-03-10] [#8-K-2026-03-10].

As of 2026-04-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 filing to confirm burn and runway after Phase 3 prep
Sustained Phase 3 enrollment and external validation of RAP-219 platform value

Scenarios

Bull Target (Scenario probability)

$52 / p=25% prob

Base Target (Scenario probability)

$38 / p=45% prob

Bear Target (Scenario probability)

$24 / p=30% prob

Analysis 2026-04-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
RAP-219 Phase 3 program initiation in focal onset seizures
The clearest forward catalyst is execution against management's stated plan to initiate two parallel global Phase 3 trials in the second quarter of 2026 after the December 2025 end-of-Phase-2 FDA meeting supported advancement into Phase 3; a visible start would modestly de-risk the story, while any slip would likely hurt sentiment [#10-K-2026-03-10].
Prob 65.00% • Move 18.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Q1 2026 filing to confirm burn and runway after Phase 3 prep
2026-05-15
The next quarterly filing should show whether cash burn is tracking consistently with management's statement that $490.5 million of cash, cash equivalents and short-term investments at December 31, 2025 can fund operations into the second half of 2029 as RAP-219 moves toward late-stage development [#10-K-2026-03-10] [#8-K-2026-03-10].
Prob 80% • Move 9% • Priced-in 55%

Long-term Catalysts

Months to a year

Sustained Phase 3 enrollment and external validation of RAP-219 platform value
2026-12-31
Longer term upside depends on Rapport showing it can enroll and run the two planned RAP-219 Phase 3 studies at scale while converting the Tenacia Greater China deal into tangible economics beyond the disclosed $20 million upfront and potential milestone structure; this is meaningful but still early and execution-heavy [#10-K-2026-03-10].
Prob 40% • Move 28% • Priced-in 25%

Risks

Cash burn accelerates as late-stage studies ramp, reviving dilution risk despite stated runway into 2H29.
Phase 2a tolerability and efficacy do not translate cleanly into larger registrational trials.
Phase 3 initiation slips beyond Q2 2026 or design/execution changes reduce confidence.
Sparse near-term news flow can leave the stock vulnerable to de-rating in risk-off biotech tape.

Peers

Symbol	Summary
BHVN	Biohaven is the closest listed neuroscience-development comparator in the candidate set, though it is broader and better covered than Rapport; useful for how CNS pipeline optionality can move valuation ahead of registrational data.
DFTX	Definium is a looser small-cap development-stage biotech comparator, but it is relevant for milestone-driven valuation swings, financing sensitivity, and the market's reaction to execution updates in pre-commercial biotech.
ORKA	Oruka is not a direct CNS peer, but its similar market cap makes it a rough comparator for small-cap biotech capital-markets behavior when company-specific catalysts are sparse.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-17

Loading AI feed…

Symbol

Summary

BHVN

Biohaven is the closest listed neuroscience-development comparator in the candidate set, though it is broader and better covered than Rapport; useful for how CNS pipeline optionality can move valuation ahead of registrational data.

DFTX

Definium is a looser small-cap development-stage biotech comparator, but it is relevant for milestone-driven valuation swings, financing sensitivity, and the market's reaction to execution updates in pre-commercial biotech.

ORKA

Oruka is not a direct CNS peer, but its similar market cap makes it a rough comparator for small-cap biotech capital-markets behavior when company-specific catalysts are sparse.